Alzheimer's disease (AD) is a complex disease. It doesn't conform to one-size-fits-all treatments. Scientists believe a multi-prong approach, which uses different medications, can help most people. Here is a summary of the current AD medications.
Current Medication Options
The FDA ha approved four AD medications. However, they don't affect everyone in the same way, and the benefits can diminish over time.
The four medications (with some brand name examples) are:
- donepezil (Aricept)
- for mild, moderate, and severe AD symptoms
- Common side effects include nausea, vomiting, and diarrhea
- galantamine (Razadyne)
- for mild and moderate AD symptoms
- common side effects include nausea, vomiting, diarrhea, weight loss, and loss of appetite
- memantine (Namenda)
- for moderate and severe AD symptoms, but not for mild AD symptoms (as currently, there's little evidence of benefit in the early-stages of AD)
- common side effects include dizziness, headache, constipation, and confusion
- rivastigmine (Exelon)
To learn more, read about drugs for Alzheimer’s disease.
How Do These Medications Work?
These medications control the chemicals that transmit messages between neurons called "neurotransmitters." This helps to maintain thinking and memory, and manage some behavioral problems.
Which Medication is Best?
No published study has compared the four drugs. However they appear to work in similar ways. For example, they all affect the level of a neurotransmitter called acetylcholine. Switching from one medication to another will not produce different results.
What About Non AD-Specific Medications?
Some medications can temporarily treat, or at least ease, AD symptoms. These include antidepressants, anti-anxiety drugs, sleep aids, and antipsychotics. They help with sleeplessness, agitation, anxiety, anger, severe aggression, wandering, and depression.
It is essential to consult an experienced AD doctor in order to receive the maximum benefit from medication. To learn more, read about drugs for Alzheimer’s disease.
- Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement.
- Alzheimer's Association. (2011). Press Release: New Criteria and Guidelines for the Diagnosis of Alzheimer's Disease Published for the first Time in 27 Years. The Alzheimer's Association, 1-11.
- Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004). Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol, 61(5), 661-666.
- Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011). Alzheimer's disease. Lancet, 377(9770), 1019-1031.
- Bird, T. D. (2010). Early-Onset Familial Alzheimer Disease. University of Washington, Gene Review.
- Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev(1), CD003120.
- Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011). Possible implications of Insulin Resistance and Glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med.
- Boyle, P. A., Buchman, A. S., Barnes, L. L., & Bennett, D. A. (2010). Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry, 67(3), 304-310.
- Boyle, P. A., Buchman, A. S., Barnes, L. L., James, B. D., & Bennett, D. A. (2010). Association between life space and risk of mortality in advanced age. J Am Geriatr Soc, 58(10), 1925-1930.
- Brinkley, T. E., Lovato, J. F., Arnold, A. M., Furberg, C. D., Kuller, L. H., Burke, G. L., et al. (2010). Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens, 23(5), 528-533.
- Daviglus, M. L., Bell, C. C., Berrettini, W., Bowen, P. E., Connolly, E. S., Cox, N. J., et al. (2010). NIH State-of-the-Science Conference Statement: Preventing Alzheimer's Disease and Cognitive Decline. NIH Consens State Sci Statements, 27(4).
- De Felice, F. G., Vieira, M. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., et al. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A, 106(6), 1971-1976.
- deIpolyi, A. R., Rankin, K. P., Mucke, L., Miller, B. L., & Gorno-Tempini, M. L. (2007). Spatial cognition and the human navigation network in AD and MCI. Neurology, 69(10), 986-997.
- DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300(19), 2253-2262.
- Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M. S., Birren, J. E., Cotman, C. W., et al. (2002). Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc, 77(7), 681-696.
- Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet, 41(10), 1088-1093.
- Herrmann, W., & Obeid, R. (2011). Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med, 49(3), 435-441.
- Keating, D. J., Chen, C., & Pritchard, M. A. (2006). Alzheimer's disease and endocytic dysfunction: clues from the Down syndrome-related proteins, DSCR1 and ITSN1. Ageing Res Rev, 5(4), 388-401.
- Ladika, D. J., & Gurevitz, S. L. (2011). Identifying the most common causes of reversible dementias: a review. JAAPA, 24(3), 28-31, 57.
- Li, K., Dai, D., Zhao, B., Yao, L., Yao, S., Wang, B., et al. (2010). Association between the RAGE G82S polymorphism and Alzheimer's disease. J Neural Transm, 117(1), 97-104.
- McKhanna, G. M., Knopmanc, D. S., Chertkowd, H., Hyman, B. T., Clifford R. Jack, J., Kawash, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup.Alzheimer’s & Dementia, 1–7.
- Nation, D. A., Hong, S., Jak, A. J., Delano-Wood, L., Mills, P. J., Bondi, M. W., et al. (2011). Stress, exercise, and Alzheimer's disease: A neurovascular pathway. Med Hypotheses.
- National Library of Medicine. (2011). Alzheimer's Disease. Medline Plus; U.S. National Library of Medicine; National Institutes of Health.
- NCCAM. (2011). National Center for Complementary and Alternative Medicine: The Ginkgo Evaluation of Memory (GEM) Study. National Institutes of Health' National Center for Complementary and Alternative Medicine.
- NIA. (2008). Alzheimer's Disease: Unraveling the Mystery. National Institute on Aging; National Institutes of Heath; US Department of Health and Human Services; NIH Publication Number 08-3782, 1-43.
- NIA. (2011). Caring for a Person with Alzheimer's Disease; Medicine Chart. National Institutes of Health; National Institute on Aging; Alzheimer's Disease Education & Referral Center.
- NINDS. (2010). NINDS Alzheimer's Disease Information Page. National Institute of Neurological Disorders and Stroke; National Institutes of Health; US Department of Health & Human Services.
- NINDS. (2011). Dementia: Hope Through Research. National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
- Panza, F., Frisardi, V., Imbimbo, B. P., D'Onofrio, G., Pietrarossa, G., Seripa, D., et al. (2010). Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy, 2(6), 767-782.
- Redish, A. D. (2001). The hippocampal debate: are we asking the right questions? Behav Brain Res, 127(1-2), 81-98.
- Reitz, C., Brayne, C., & Mayeux, R. (2011). Epidemiology of Alzheimer disease. Nat Rev Neurol, 7(3), 137-152.
- Reitz, C., den Heijer, T., van Duijn, C., Hofman, A., & Breteler, M. M. (2007). Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology, 69(10), 998-1005.
- Seneff, S., Wainwright, G., & Mascitelli, L. (2011). Nutrition and Alzheimer's disease: The detrimental role of a high carbohydrate diet.Eur J Intern Med, 22(2), 134-140.
- Snitz, B. E., O'Meara, E. S., Carlson, M. C., Arnold, A. M., Ives, D. G., Rapp, S. R., et al. (2009). Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA, 302(24), 2663-2670.
- Solomon, P. R., Adams, F., Silver, A., Zimmer, J., & DeVeaux, R. (2002). Ginkgo for memory enhancement: a randomized controlled trial. JAMA, 288(7), 835-840.
- Traykov, L., Rigaud, A. S., Cesaro, P., & Boller, F. (2007). [Neuropsychological impairment in the early Alzheimer's disease].Encephale, 33(3 Pt 1), 310-316.
- Uc, E. Y., Rizzo, M., Anderson, S. W., Shi, Q., & Dawson, J. D. (2004). Driver route-following and safety errors in early Alzheimer disease.Neurology, 63(5), 832-837.
- Wegiel, J., Gong, C. X., & Hwang, Y. W. (2011). The role of DYRK1A in neurodegenerative diseases. FEBS J, 278(2), 236-245.
- Wilson, R. S., Mendes De Leon, C. F., Barnes, L. L., Schneider, J. A., Bienias, J. L., Evans, D. A., et al. (2002). Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287(6), 742-748.
- Yu, F. (2011). Guiding Research and Practice: A Conceptual Model for Aerobic Exercise Training in Alzheimer's Disease. Am J Alzheimers Dis Other Demen.